Intravenous Famotidine Dosing After Epinephrine in Anaphylaxis
For adults, administer 50 mg IV famotidine (or alternatively ranitidine 50 mg IV), and for children, administer 1 mg/kg IV famotidine (maximum 20 mg), diluted in 5% dextrose to 20 mL total volume and injected over 5 minutes. 1
Adult Dosing
The established guideline dose for H2-antihistamines in anaphylaxis management is:
- Ranitidine: 50 mg IV (diluted in D5W to 20 mL, given over 5 minutes) 1
- Cimetidine: 4 mg/kg IV (alternative) 1
While the guidelines specifically reference ranitidine and cimetidine, famotidine is the H2-blocker currently available in most settings given ranitidine's market withdrawal. The FDA-approved adult dose for famotidine IV is 20 mg every 12 hours 2, though the anaphylaxis context may warrant consideration of the higher ranitidine-equivalent dosing of approximately 40-50 mg based on relative potency.
Pediatric Dosing
For children: 1 mg/kg IV (range 12.5-50 mg based on weight), diluted in D5W to 20 mL and administered over 5 minutes 1. This translates to:
- Maximum dose: 20 mg (based on standard famotidine dosing)
- Minimum practical dose: 12.5 mg for smaller children
The FDA label supports 0.25 mg/kg IV every 12 hours (maximum 40 mg/day) for pediatric patients 1-16 years 2, but the anaphylaxis guidelines recommend the higher 1 mg/kg dose for acute management 1.
Critical Context and Caveats
Role as Second-Line Therapy
H2-antihistamines are strictly second-line therapy to epinephrine and should NEVER be used alone in anaphylaxis treatment 1. They have a much slower onset of action than epinephrine. The combination of H1-antihistamine (diphenhydramine 1-2 mg/kg or 25-50 mg) plus H2-antihistamine is superior to H1-antihistamine alone 1.
Administration Technique
- Dilute in 5% dextrose (D5W) to total volume of 20 mL
- Inject IV over 5 minutes 1
- Can be given undiluted IV push over 2 minutes per FDA labeling 2, though slower administration is preferred in the anaphylaxis setting
Safety Profile
Recent pediatric data demonstrates that undiluted famotidine IV push produces no clinically significant hemodynamic adverse effects in critically ill children 3. Only 3.4% of patients required vasoactive medication adjustment, and these were postoperative cardiac surgery patients with confounding factors 3. Adult data similarly shows no clinically important hemodynamic changes 4.
Renal Dosing Adjustments
For patients with moderate to severe renal insufficiency (CrCl <50 mL/min), reduce dose to half or prolong dosing interval to 36-48 hours 2. This applies to both adult and pediatric patients.